Valeant Unit Sued by Pension Fund Over Solodyn Monopoly

Valeant Pharmaceuticals International Inc. (VRX) was sued by a pension fund over allegations its Medicis unit conspired to preserve a monopoly on the acne drug Solodyn.

Medicis “orchestrated a multi-faceted scheme” to delay generic competition by filing sham citizens’ petitions with the U.S. Food and Drug Administration, according to the complaint filed yesterday in federal court in Philadelphia. Medicis also entered into unlawful agreements with generic manufacturers including Impax Laboratories Inc. (IPXL), which got at least $55 million to drop a patent challenge, according to the filing.

Impax was named as a defendant in the case, along with Teva Pharmaceutical Industries Ltd. (TEVA), Mylan Inc., Ranbaxy Laboratories Ltd. and Novartis AG’s Sandoz unit.

Julie Masow, a spokeswoman for Basel, Switzerland-based Novartis, declined to comment on the complaint. Officials at Bridgewater, New Jersey-based Valeant didn’t immediately respond to an e-mail seeking comment.

Nina Devlin, a spokeswoman for Canonsburg, Pennsylvania-based Mylan, didn’t immediately respond to a phone call seeking comment. Denise Bradley, a spokeswoman for Petach Tikva, Israel-based Teva, and Dawn Wolfe and Sharon Santacroce, spokeswomen for India’s Ranbaxy, didn’t immediately respond to e-mails seeking comment.

The case is United Food and Commercial Workers Local 1776 & Participating Employers Health and Welfare Fund, 13-4235, U.S. District Court Eastern District of Pennsylvania (Philadelphia).

To contact the reporter on this story: Sophia Pearson in Philadelphia federal court at spearson3@bloomberg.net

To contact the editor responsible for this story: Michael Hytha at mhytha@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.